Laura Chico
Stock Analyst at Wedbush
(4.17)
# 437
Out of 5,163 analysts
247
Total ratings
50.88%
Success rate
13.73%
Average return
Main Sectors:
Stocks Rated by Laura Chico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLDB Solid Biosciences | Maintains: Outperform | $14 → $17 | $7.31 | +132.56% | 5 | Mar 12, 2026 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $80 → $103 | $77.86 | +32.29% | 14 | Mar 12, 2026 | |
| VRDN Viridian Therapeutics | Reiterates: Outperform | $44 | $28.68 | +53.42% | 9 | Mar 11, 2026 | |
| XENE Xenon Pharmaceuticals | Maintains: Outperform | $47 → $64 | $55.23 | +15.88% | 10 | Mar 10, 2026 | |
| JBIO Jade Biosciences | Reiterates: Outperform | $24 | $13.92 | +72.41% | 4 | Mar 9, 2026 | |
| CLYM Climb Bio | Maintains: Outperform | $12 → $14 | $7.03 | +99.15% | 2 | Mar 6, 2026 | |
| LRMR Larimar Therapeutics | Maintains: Outperform | $11 → $12 | $4.60 | +161.15% | 5 | Mar 3, 2026 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $20 → $18 | $18.94 | -4.96% | 15 | Feb 25, 2026 | |
| GOSS Gossamer Bio | Downgrades: Neutral | $6 → $1 | $0.44 | +128.78% | 7 | Feb 24, 2026 | |
| ARDX Ardelyx | Reiterates: Outperform | $19 | $5.78 | +228.72% | 16 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $95 → $130 | $293.95 | -55.77% | 12 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $25 | $21.34 | +17.15% | 15 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $149 → $151 | $129.78 | +16.35% | 11 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $178 → $187 | $181.55 | +3.00% | 20 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $36 | $33.19 | +8.47% | 9 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $30 | $20.57 | +45.84% | 10 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $23 → $33 | $39.96 | -17.42% | 9 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $30 | $25.42 | +18.02% | 8 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $36 | $50.21 | -28.30% | 2 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $32 | $29.59 | +8.14% | 11 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $8 | $5.33 | +50.23% | 12 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $32 | $27.80 | +15.11% | 12 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $18 | $8.22 | +118.98% | 1 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $4 | $22.26 | -82.03% | 4 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $3 | $1.97 | +52.28% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $4.46 | +57.13% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $104 → $88 | $9.36 | +840.17% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $10.12 | -50.59% | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $58.51 | - | 5 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $4.49 | +11.36% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $149 | $9.58 | +1,450.10% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $720 | $9.41 | +7,551.43% | 1 | Jan 19, 2018 |
Solid Biosciences
Mar 12, 2026
Maintains: Outperform
Price Target: $14 → $17
Current: $7.31
Upside: +132.56%
Dianthus Therapeutics
Mar 12, 2026
Maintains: Outperform
Price Target: $80 → $103
Current: $77.86
Upside: +32.29%
Viridian Therapeutics
Mar 11, 2026
Reiterates: Outperform
Price Target: $44
Current: $28.68
Upside: +53.42%
Xenon Pharmaceuticals
Mar 10, 2026
Maintains: Outperform
Price Target: $47 → $64
Current: $55.23
Upside: +15.88%
Jade Biosciences
Mar 9, 2026
Reiterates: Outperform
Price Target: $24
Current: $13.92
Upside: +72.41%
Climb Bio
Mar 6, 2026
Maintains: Outperform
Price Target: $12 → $14
Current: $7.03
Upside: +99.15%
Larimar Therapeutics
Mar 3, 2026
Maintains: Outperform
Price Target: $11 → $12
Current: $4.60
Upside: +161.15%
Apellis Pharmaceuticals
Feb 25, 2026
Maintains: Neutral
Price Target: $20 → $18
Current: $18.94
Upside: -4.96%
Gossamer Bio
Feb 24, 2026
Downgrades: Neutral
Price Target: $6 → $1
Current: $0.44
Upside: +128.78%
Ardelyx
Feb 23, 2026
Reiterates: Outperform
Price Target: $19
Current: $5.78
Upside: +228.72%
Feb 20, 2026
Maintains: Underperform
Price Target: $95 → $130
Current: $293.95
Upside: -55.77%
Feb 17, 2026
Reiterates: Neutral
Price Target: $25
Current: $21.34
Upside: +17.15%
Feb 12, 2026
Maintains: Outperform
Price Target: $149 → $151
Current: $129.78
Upside: +16.35%
Feb 10, 2026
Maintains: Neutral
Price Target: $178 → $187
Current: $181.55
Upside: +3.00%
Jan 12, 2026
Maintains: Outperform
Price Target: $32 → $36
Current: $33.19
Upside: +8.47%
Dec 11, 2025
Maintains: Outperform
Price Target: $31 → $30
Current: $20.57
Upside: +45.84%
Dec 11, 2025
Maintains: Neutral
Price Target: $23 → $33
Current: $39.96
Upside: -17.42%
Nov 13, 2025
Maintains: Outperform
Price Target: $27 → $30
Current: $25.42
Upside: +18.02%
Nov 7, 2025
Maintains: Outperform
Price Target: $35 → $36
Current: $50.21
Upside: -28.30%
Nov 7, 2025
Maintains: Outperform
Price Target: $35 → $32
Current: $29.59
Upside: +8.14%
Sep 30, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $5.33
Upside: +50.23%
Aug 7, 2025
Maintains: Outperform
Price Target: $30 → $32
Current: $27.80
Upside: +15.11%
Jun 30, 2025
Maintains: Outperform
Price Target: $16 → $18
Current: $8.22
Upside: +118.98%
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $22.26
Upside: -82.03%
Mar 12, 2025
Maintains: Outperform
Price Target: $4 → $3
Current: $1.97
Upside: +52.28%
Aug 7, 2024
Maintains: Neutral
Price Target: $8 → $7
Current: $4.46
Upside: +57.13%
Apr 11, 2024
Maintains: Outperform
Price Target: $104 → $88
Current: $9.36
Upside: +840.17%
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $10.12
Upside: -50.59%
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $58.51
Upside: -
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $4.49
Upside: +11.36%
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $9.58
Upside: +1,450.10%
Jan 19, 2018
Initiates: Outperform
Price Target: $720
Current: $9.41
Upside: +7,551.43%